## Rita O Oladele

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/7893420/publications.pdf

Version: 2024-02-01

36 papers 3,877 citations

623188 14 h-index 35 g-index

36 all docs 36 docs citations

36 times ranked 4825 citing authors

#	Article	IF	Citations
1	Global and Multi-National Prevalence of Fungal Diseases—Estimate Precision. Journal of Fungi (Basel,) Tj ETQq1	1 0.784314 1.5	1,7gBT /Over 1,642
2	Global guideline for the diagnosis and management of mucormycosis: an initiative of the European Confederation of Medical Mycology in cooperation with the Mycoses Study Group Education and Research Consortium. Lancet Infectious Diseases, The, 2019, 19, e405-e421.	4.6	970
3	Defining and managing COVID-19-associated pulmonary aspergillosis: the 2020 ECMM/ISHAM consensus criteria for research and clinical guidance. Lancet Infectious Diseases, The, 2021, 21, e149-e162.	4.6	586
4	Histoplasmosis in Africa: An emerging or a neglected disease?. PLoS Neglected Tropical Diseases, 2018, 12, e0006046.	1.3	125
5	A systematic review of fluconazole resistance in clinical isolates of <i>Cryptococcus</i> species. Mycoses, 2018, 61, 290-297.	1.8	109
6	Diagnosing Pneumocystis jirovecii pneumonia: A review of current methods and novel approaches. Medical Mycology, 2020, 58, 1015-1028.	0.3	90
7	Leave no one behind: response to new evidence and guidelines for the management of cryptococcal meningitis in low-income and middle-income countries. Lancet Infectious Diseases, The, 2019, 19, e143-e147.	4.6	63
8	The current state of clinical mycology in Africa: a European Confederation of Medical Mycology and International Society for Human and Animal Mycology survey. Lancet Microbe, The, 2022, 3, e464-e470.	3.4	35
9	Incidence, Clinical Outcome and Risk Factors of Intensive Care Unit Infections in the Lagos University Teaching Hospital (LUTH), Lagos, Nigeria. PLoS ONE, 2016, 11, e0165242.	1.1	31
10	Cryptococcal Antigenemia in Nigerian Patients With Advanced Human Immunodeficiency Virus: Influence of Antiretroviral Therapy Adherence. Open Forum Infectious Diseases, 2016, 3, ofw055.	0.4	20
11	Prevalence of Tinea capitis infection among primary school children in a rural setting in south-west Nigeria. Journal of Public Health in Africa, 2014, 5, 349.	0.2	19
12	Bridging the knowledge gap on mycoses in Africa: Setting up a Panâ€African Mycology Working Group. Mycoses, 2020, 63, 244-249.	1.8	18
13	Prior subclinical histoplasmosis revealed in Nigeria using histoplasmin skin testing. PLoS ONE, 2018, 13, e0196224.	1.1	17
14	Fluconazole Resistance among Oral Candida Isolates from People Living with HIV/AIDS in a Nigerian Tertiary Hospital. Journal of Fungi (Basel, Switzerland), 2017, 3, 69.	1.5	16
15	Evaluation of knowledge and awareness of invasive fungal infections amongst resident doctors in Nigeria. Pan African Medical Journal, 2020, 36, 297.	0.3	16
16	Mycetoma in West Africa. Transactions of the Royal Society of Tropical Medicine and Hygiene, 2021, 115, 328-336.	0.7	15
17	Histoplasmosis in Africa: Current perspectives, knowledge gaps, and research priorities. PLoS Neglected Tropical Diseases, 2022, 16, e0010111.	1.3	12
18	Histoplasmosis in Children; HIV/AIDS Not a Major Driver. Journal of Fungi (Basel, Switzerland), 2021, 7, 530.	1.5	11

#	Article	IF	Citations
19	Fluconazole susceptibility and ERG11 gene expression in vaginal candida species isolated from Lagos Nigeria. International Journal of Molecular Epidemiology and Genetics, 2012, 3, 84-90.	0.4	11
20	Establishing targets for advanced HIV disease: A call to action. Southern African Journal of HIV Medicine, 2021, 22, 1266.	0.3	9
21	Treatment outcome definitions in chronic pulmonary aspergillosis: a CPAnet consensus statement. European Respiratory Journal, 2022, 59, 2102950.	3.1	9
22	The role of medical mycology societies in combating invasive fungal infections in low―and middle―ncome countries: A Nigerian model. Mycoses, 2019, 62, 16-21.	1.8	8
23	Invasive candidiasis in a neonatal intensive care unit in Lagos, Nigeria. Nigerian postgraduate medical journal, The, 2017, 24, 150.	0.1	7
24	Histoplasmosis in African children: clinical features, diagnosis and treatment. Therapeutic Advances in Infectious Disease, 2022, 9, 204993612110685.	1.1	6
25	Tackling cryptococcal meningitis in Nigeria, one-step at a time; the impact of training. PLoS ONE, 2020, 15, e0235577.	1.1	5
26	Nutritional immunity: targeting fungal zinc homeostasis. Heliyon, 2021, 7, e07805.	1.4	5
27	Our pursuit for effective antifungal agents targeting fungal cell wall components: where are we?. International Journal of Antimicrobial Agents, 2022, 59, 106477.	1.1	5
28	Triazole susceptibility of <i>Aspergillus</i> species: environmental survey in Lagos, Nigeria and review of the rest of Africa. Therapeutic Advances in Infectious Disease, 2021, 8, 204993612110443.	1.1	4
29	Prospective Evaluation of Positivity Rates of Aspergillus-Specific IgG and Quality of Life in HIV-Negative Tuberculosis Patients in Lagos, Nigeria. Frontiers in Cellular and Infection Microbiology, 2022, 12, 790134.	1.8	3
30	Cryptococcal meningitis after ART: Need for proper baseline evaluation in the era of †Test & Treat'. Medical Mycology Case Reports, 2019, 24, 58-60.	0.7	2
31	Melioidosis in Africa: Time to Raise Awareness and Build Capacity for Its Detection, Diagnosis, and Treatment. American Journal of Tropical Medicine and Hygiene, 2022, 106, 394-397.	0.6	2
32	Pediatric brain abscess – etiology, management challenges and outcome in Lagos Nigeria. , 2021, 12, 592.		2
33	Car windshield fragments as cheap alternative glass beads for homogenization of Mycobacterium tuberculosis cultures in a resource-limited setting. International Journal of Mycobacteriology, 2014, 3, 46.	0.3	1
34	Closing the knowledge gap in mycology in Nigeria by leveraging e-learning: perspectives from the field. Therapeutic Advances in Infectious Disease, 2021, 8, 204993612110216.	1.1	1
35	Standardization of Aspergillus IgG diagnostic cutoff in Nigerians. Therapeutic Advances in Infectious Disease, 2021, 8, 204993612110501.	1.1	1
36	Disseminated histoplasmosis in an AIDS patient with immunologic non-response to HAART: A case report. Journal De Mycologie Medicale, 2022, 32, 101271.	0.7	1